ALFA Finder| Management target | Revenue FY28 |
|---|
| Revenue growth | Consolidated revenue grew 21% YoY to ₹115 Cr. |
|---|---|
| Margins | Gross margins contracted 500 bps due to crude price spikes. |
| Demand visibility | Strong uptake in pharma and healthcare; export inquiries rising. |
| Management confidence | Optimistic on volume recovery despite external raw material headwinds. |
Growth
Revenue grew 21% YoY, primarily volume-led by the domestic pharma and export segments.
Outlook
Revenue potential of ₹800 Cr expected across old and new facilities by FY28.
Risks
Raw material costs surged 30-50%, leading to a 500 bps gross margin contraction.
Last quarter's promises, checked
Delivered
- Guided FY27 growth ≥15% → Q2 revenue +21% YoY (= BEAT)
Partly delivered
- Guided ₹40-50 Cr debt cut YoY → gross debt ₹380 Cr (Q1) to ₹370-380 Cr (Q2) (= PARTIAL)
- Guided Panchla+Amta 20-25% of FY28 standalone revenue → FY28 not reached, unverifiable (= PARTIAL)
Missed
- Guided full commissioning in Q2 FY27 → final phase ongoing; only cell culture and radiation lines live (= MISS)
- Guided price hikes fully flow through with one-quarter lag → inflation not fully offset (= MISS)
Earnings Call Transcript filed with NSE, NSE: TARSONS. Summary written with AI assistance from the document.
Tarsons Products Ltd: key numbers
- Share price
- ₹315.45
- Market cap
- ₹1,678 Cr
- Revenue (annual)
- ₹422.5 Cr
- Net profit (annual)
- ₹14.32 Cr
- P/E (TTM)
- 225.9×Sector 55.1×
- Promoter holding
- 47.30%+0.00% QoQ
- FII holding
- 0.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tarsons Products Ltd
All →Tarsons Products Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs123.7 cr (+21%), EBITDA Rs31.1 cr (25.1% margin), net loss Rs0.3 cr vs Rs3.3 cr profit; capacity expansion at Amta and Panchla.
Tarsons Products Q2 FY27 Results: Net Loss of ₹0.3 Cr
Tarsons Products Ltd reported revenue from operations of ₹123.7 Cr (+20.9% YoY) and a net loss of ₹0.3 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.3 Cr
Tarsons Products Board Meeting Date
Tarsons Products will hold a board meeting on November 12, 2026 to consider unaudited standalone and consolidated half-year results for September 2026. The trading window is closed from October 1 to November 14, 2026.
Tarsons Products Other Announcement
Tarsons Products Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Tarsons Products Management Change
Tarsons Products Limited re-appointed Sanjive Sehgal as Executive Director following his retirement by rotation. This filing updates his directorial status.
Tarsons Products Annual General Meeting
Tarsons Products Limited held its 43rd Annual General Meeting on September 24, 2026, through video conferencing. Shareholders discussed financial statements and approved various resolutions.